Oxstem

OxStem is a drug discovery company, spun-out from the University of Oxford in 2016, with the unique vision of developing small molecule therapeutics that augment repair mechanisms that already exist within the body. OxStem is developing drug candidates that can awaken endogenous cells to repair tissues affected by disease or injury to treat diseases such as Dementia, Heart Failure, Macular Degeneration (the leading cause of blindness in the developed world) and Oncology.

Company Type
Twitter Account
@OxStem

PCI Pharma Services

PCI is a leading provider of integrated pharmaceutical development services to the global healthcare market. With facilities in North America and Europe, PCI supports pharmaceutical and biotech companies with products destined for more than 100 countries around the world. PCI provides services for each stage of the product lifecycle - from early Phase I through commercial launch and long-term supply - and partners with customers to provide key insight and expertise in enabling successful commercialization and bringing lifesaving medications to patients.

Precision Oncology

    Precision Oncology is proud to offer the first comprehensive, fully integrated oncology clinical development solution. We are devoted exclusively to oncology, and passionate about improving the lives of cancer patients. By combining the progressive science of biomarkers and analytics with our excellence in oncology clinical trial execution, we help innovators to invest wisely, discover value sooner and optimize the returns from research.
Company Type
Company Sub-Type
Twitter Account
@PrecisionOnc

Sareum

Sareum is a drug discovery and development company, headquartered in Cambridge UK, that produces targeted small molecule therapeutics, focusing on cancer and autoimmune disease. Sareum aims to successfully deliver drug candidates for licensing to pharmaceutical and biotechnology companies at the pre-clinical or early clinical trials stage.

Sareum operates an outsourced research model, working with collaborators (SRI International, the CRT Pioneer Fund and Hebei Medical University Biomedical Engineering Center) and a world-wide network of research providers. Its research pipeline includes two programmes undergoing pre-clinical IND-enabling studies.

Selcia Ltd

Selcia Ltd is a leading provider of contract research services in drug discovery and 14C radiolabelling.

Selcia Drug Discovery focusses on integrated small molecule drug discovery, with a strong track record of IP generation and preclinical candidate delivery for customers – 25 patents and 11 preclinical candidates generated.  USPs are the medicinal chemistry of macrocycles, and a peptidyl prolyl isomerase (PPIase) screening platform.

Selcia radiolabelling specialises in 14C GMP radiolabelling, producing 14C radiolabelled compounds for a global customer base encompassing both the life sciences and chemical industries. Applications of the radiolabelled products prepared by Selcia include: preclinical and clinical drug metabolism studies; mass balance, IV microdosing, dermal penetration, regulatory and environmental fate studies.

Selcia also offers GLP NMR and mass spectrometry services to support regulatory submissions, and specialised purification capabilities from analytical (µg) to multi-100g scale.

Areas of Expertise:

• Medicinal chemistry:  Tool compounds; peptides; macrocycles; natural product chemistry

• Biology: Assay development; ADME screens;  PPIase profiling

• Disease expertise: Anti-infectives; inflammation; CNS; pain; metabolic; oncology & ophthalmology

• Target classes: GPCRs; ion channels; enzymes; protein-protein interactions

• 14C Custom Radiosynthesis

• GMP 14C Radiolabelled API for Clinical Trials

• GLP/GMP Analytics – GLP NMR

• Metabolites and Impurities (Profiling and Synthesis), standards and stable labelled compounds

contact@selcia.com

Company Type
Company Sub-Type
Keywords
Twitter Account
@SelciaLtd

Sphere Fluidics

Encapsulating Biology, Transforming Discovery. #SphereFluidics is developing picodroplets and single cell analysis systems and services for therapeutic discovery.

Specialties:
biopharmaceutical, lab-on-a-chip, cells, antibodies, microfluidics, enzymes, cancer, biologics, biotechnology, pharmaceutical, life sciences, immunology, oncology, cell therapies, and stem cells

Company Type
Company Sub-Type
Twitter Account
@SphereFluidics

Sygnature Discovery Ltd

Sygnature Discovery is the UK’s largest independent provider of integrated drug discovery resource and expertise.  Founded in 2004, Sygnature undertakes complete drug discovery programmes and target validation, hit identification, hit-to-lead and lead optimisation projects for pharmaceutical and biotech companies.  Core capabilities include medicinal and synthetic chemistry, in vitro biology/screening, computational chemistry, DMPK and protein crystallography.  Sygnature has an enviable track record of success in delivering multiple clinical candidates.

Winner of OBN Best Synthetic Biology Company Award.

Company Type
Company Sub-Type
Twitter Account
@SygnatureDiscov

Syne qua non Ltd

Syne qua non Limited (SQN) is one of the world’s recognised specialist clinical biometrics CROs supporting global pharma, biotech, medical device and animal health partners with innovative clinical development services.  SQN was previously honoured with a Queen’s Award for Enterprise in 2009, in the international trade category in recognition of our business growth and export performance. We are extremely proud to have won the 2017 Queen’s Award for Innovation for Syne-clin, our innovative EDC and Trial Management system.

Utilising standard validated library elements to build each study system, Syne-clin delivers significant time and cost savings and shortens the drug development cycle, accelerating the process of getting new medical treatments to market. Incorporating mobile, tablet and smartphone device data collection, Syne-clin allows real-time collection of patient clinical outcomes utilising electronic diary and questionnaire functionality.

Our technology and innovation project has also allowed SQN to successfully compete internationally and win clinical research projects from overseas competition thus supporting and enhancing the reputation of the UK as a centre of excellence for pharmaceutical and healthcare research. This trend continues as the rapid and ongoing development of mobile and wearable devices creates opportunities to collect patient data in ways previously not possible. Our technology incorporates these developments and allows enhanced functionality and added value, this will allow us to continue to increase market share and generate new business opportunities.

For a demo of the system come and see us at Stand 89A

Company Type
Company Sub-Type
Twitter Account
@Synequanon

Synpromics Ltd

Synpromics is a life science company focused on the field of synthetic biology. The Company's proprietary technology enables the design of optimized synthetic promoters that provide more effective and efficient gene regulation.

Winner of OBN Best Contract Research Organisation Award 2017 

and 

Winner of OBN Best Synthetic Biology Company Award.

Company Type
Company Sub-Type
Twitter Account
@synpromics

SYNthesis Med Chem

SYNthesis med chem a chemistry-focussed contract research organisation that carries out custom synthesis, medicinal chemistry and integrated drug discovery projects for biotech & pharma companies and research institutes. In addition to providing chemistry services, SYNthesis also establishes shared risk collaborations with partners, the goal being to identify, develop and partner small molecule drugs.